What is Kala Pharmaceuticals Inc (KALA) stock price today?

Kala Pharmaceuticals Inc (KALA) currently trades at $0.11 per share. The stock has a market capitalization of $110.98M and a P/E ratio of —x.

Is KALA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Kala Pharmaceuticals Inc has a Smart Value Score of 14/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -18.43.

Is Kala Pharmaceuticals Inc financially healthy?

Kala Pharmaceuticals Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -18.43 places it in the distress.

KALA

Kala Pharmaceuticals Inc

NASDAQ: KALA · HEALTHCARE · BIOTECHNOLOGY

$0.11

-3.93% today

Updated 2026-04-30

Market cap

$110.98M

P/E ratio

—

P/S ratio

23.75x

EPS (TTM)

$-3.31

Dividend yield

—

52W range

$0 – $21

Volume

9.1M

Market cap

$110.98M

P/E ratio

—

P/S ratio

23.75x

EPS (TTM)

$-3.31

Dividend yield

—

52W range

$0 – $21

Volume

9.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

4.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-18.4

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$1.50

+1327.21%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Debt/equity -3.58x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -18.43 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-4.57M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$3.89M	$0.00	$0.00	$0.00	—
Net income	$-44.82M	$-42.20M	$-38.51M	$-26.98M	$686000.00
EPS	—	—	—	—	$-3.31
Free cash flow	$-79.22M	$-28.54M	$-29.59M	$-32.01M	$-4.57M
Profit margin	-1,151.64%	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
KALA	$110.98M	14	3.7	3.0	5.0	4.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Kala Pharmaceuticals Inc trades at $0.11. Our Smart Value Score of 14/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -18.43, it sits in the distress.

Frequently asked questions

What is Kala Pharmaceuticals Inc's stock price?

Kala Pharmaceuticals Inc (KALA) trades at $0.11.

Is Kala Pharmaceuticals Inc overvalued?

Smart Value Score 14/100 (Grade F, Strong Sell).

What is the price target of Kala Pharmaceuticals Inc (KALA)?

The analyst target price is $1.50, representing +1327.2% upside from the current price of $0.11.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-18.43 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.kalarx.com

Quick metrics

P/S ratio23.75x

ROE-279.20%

Beta-1.99

50D MA$0.26

200D MA$3.41

Shares out0.93B

Float0.93B

Short ratio—

Avg volume9.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

KALA vs LLY →KALA vs JNJ →KALA vs ABBV →Stock screener →